Oncologists from NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine will discuss their latest research findings at the American Society for Clinical Oncology (ASCO) annual meeting. We will be participating in a total of 48 sessions, with two abstracts being selected for the Best of ASCO program. Details on the presentations, our presenting physicians, real-time physician commentary and related resources are detailed on this page.
For men with metastatic prostate cancer that grows despite hormonal therapy (also referred to as castration-resistant prostate cancer), chemotherapy has been a mainstay. The class of chemotherapy that has consistently proved to improve survival for men with advanced prostate cancer is called “taxanes.”
When Myrrah Shapoo arrived at NewYork-Presbyterian/Columbia University Medical Center last year with a form of cancer that wouldn’t respond to chemotherapy, a team of physicians and scientists working on a new precision-medicine initiative faced their ultimate test.
In myeloma, there are numerous choices for therapy. We recommend treatments based on the risk level of the disease. Patients are divided into two groups, standard risk and high risk. In most centers, risk categorization is an important consideration when deciding the best course of treatment. Assessing risk typically involves the underlying health and age of the patient, the extent of disease, and genetic abnormalities within the cells. The standard system to classify extent or "stage" is called the International Staging System or “ISS.” The standard method to assess genetic abnormalities is called FISH (fluorescent in situ hybridization).
Metastatic prostate cancer patients respond better to treatment when they switch to different drugs in the absence of an optimal initial response, according to new research from Weill Cornell Medicine and NewYork-Presbyterian.
A drug that recruits immune cells to fight an aggressive form of lymphoma that disproportionately affects minorities in the United States appears to be more effective than chemotherapy, according to new research from Weill Cornell Medicine and NewYork-Presbyterian.
Advances in therapeutics have led to improvements in both survival and quality of life for patients with cancer, including men with advanced prostate cancer. Simultaneously, a number of cutting-edge scientific advances have been made in the underlying biology of advanced prostate cancer. There is great potential and power in integrating these new therapeutics and biomarkers, which is often referred to precision medicine. While great advances have already been made in this area, many remain highly sophisticated and restricted to selected centers, such as Weill Cornell Medicine and NewYork-Presbyterian Hospital, while others still need validation in a larger number of patients. Ultimately, the goal is to be able to bring these technologies and treatments to cancer patients all around the country and the world.
Lutetium 177 (also known as Lu-177 or 177-Lu) is a very popular radioactive particle used to treat prostate cancer in Europe, as it has previously been shown to be effective against metastatic prostate cancer. For more than 10 years, Weill Cornell Medicine has been one of very few centers in the United States that is able to offer this as a targeted prostate cancer treatment.
Women with early-stage breast cancer for whom chemotherapy was indicated and who used dietary supplements and multiple types of complementary and alternative medicine were less likely to start chemotherapy than nonusers of alternative therapies, according to research led by Heather Greenlee, ND, PhD, Associate Professor of Epidemiology at Columbia University's Mailman School of Public Health.
The Fellow of the American Society of Clinical Oncology (FASCO) distinction recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO.
How do the bacteria swimming inside and around our guts change our chances of developing cancer? What effect might they have on the immune system? And what happens when you introduce antibiotics or anti-inflammatory drugs?
In the late 1800s, a New York surgeon named William Coley noticed that some patients with cancer seemed to fare better if they developed an infection after undergoing surgery.
From our personalities to our hair and eye colors, genetic variations make us who we are. When it comes to cancer, genetic variations can also share insights into who is most likely or least likely to respond to a particular treatment.
In phase I/II trial, new targeted therapy for hard-to-treat chronic lymphocytic leukemia appears as effective as ibrutinib with fewer side effects.
BBI608 is currently under investigation via the phase III BRIGHTER trial as a second-line treatment for patients with gastric and gastroesophageal junction cancer who have previously undergone platinum and fluoropyrimidine-based chemotherapy.
Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care.
Napabucasin, a novel oral agent that targets the STAT3 pathway, is the most advanced new drug in clinical development designed specifically to attack cancer stem cells (CSCs), a subset of the total cancer cell population that is believed to drive tumor recurrence and metastasis even after cytotoxic therapy.
In the United States, low-income ethnic minorities are more likely to be obese and thus at risk for a variety of chronic illnesses, compared with white Americans.
Cancer metastases (spreading from the initial cancer tumor to other parts of the body) account for the majority of cancer-related deaths because of poor responses to anti-cancer therapies. Researchers at Weill Cornell Medical College, in collaboration with engineers from Cornell University in Ithaca, NY, have created a new device that searches the blood for living, circulating tumor cells.